{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:09:04Z","timestamp":1791288544222,"version":"4.3.0"},"reference-count":69,"publisher":"Becaris Publishing Limited","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>\n            <jats:bold>Objective:<\/jats:bold>\n            Published network meta-analyses of chronic hepatitis B (CHB) treatments are either out-of-date or excluded key treatments. Therefore, we aimed to comprehensively update the efficacy evidence for the following end points: Hepatitis B surface antigen (HBsAg) loss, hepatitis B early antigen (HBeAg) seroconversion and hepatitis B virus DNA\u00a0(HBV DNA) suppression.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Approved treatments in CHB and their combinations were evaluated. A systematic literature review\u00a0was conducted to identify all randomized controlled trials\u00a0in treatment-na\u00efve CHB patients. Included studies reported at least one of the end points of interest. A frequentist probability network meta-analysis\u00a0was performed for each end point. The choice of fixed effect or random-effect model was based on the\u00a0I-square\u00a0statistic, a measure of variation in study outcomes between studies. The analyses were performed separately for HBeAg-positive and HBeAg-negative patients. For the primary analyses, end points measured 48\u00a0\u00b1\u00a04\u00a0weeks after treatment initiation were considered.\n            <jats:bold>Results:<\/jats:bold>\n            A total of 47 randomized controlled trials (13,826 patients), covering 23 unique treatment regimens, were included: a\u00a0total of\u00a029 reported HBsAg loss, 36 reported HBeAg seroconversion and 37 reported HBV DNA suppression. For both HBsAg loss and HBeAg seroconversion, pegylated interferon-based regimens were the most effective strategy in both HBeAg-positive and HBeAg-negative patients. On the other hand, for HBV DNA suppression, nucleosides-based regimens were the most effective strategy in both HBeAg-positive and HBeAg-negative patients.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Our findings confirm available evidence around the comparative efficacy of available CHB treatments. Therefore, they can be used to update relevant cost\u2013effectiveness analyses and clinical guidelines.\n          <\/jats:p>","DOI":"10.2217\/cer-2020-0068","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T09:49:32Z","timestamp":1600422572000},"page":"1051-1065","source":"Crossref","is-referenced-by-count":7,"title":["A comparative network meta-analysis of standard\u00a0of care treatments in treatment-na\u00efve chronic hepatitis B patients"],"prefix":"10.57264","volume":"9","author":[{"given":"Urbano","family":"Sbarigia","sequence":"first","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talitha","family":"Vincken","sequence":"additional","affiliation":[{"name":"Ingress-Health, Weena 316 Rotterdam, 3012NJ, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wigfield","sequence":"additional","affiliation":[{"name":"Ingress-Health, Weena 316 Rotterdam, 3012NJ, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[{"name":"Ingress-Health, Weena 316 Rotterdam, 3012NJ, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Heeg","sequence":"additional","affiliation":[{"name":"Ingress-Health, Weena 316 Rotterdam, 3012NJ, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[{"name":"Unit of PharmacoEpidemiology &amp; PharmacoEconomics, Rijksuniversiteit Groningen - Pharmacy, Groningen, The Netherlands"},{"name":"Institute of Science in Healthy Aging &amp; healthcaRE (SHARE), Universitair Medisch Centrum Groningen, Groningen, The Netherlands"},{"name":"Epidemiology, Universitair Medisch Centrum Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"6","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","unstructured":"Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3(6), 383\u2013403 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"e_1_3_4_4_2","unstructured":"WHO. Hepatitis B: key facts (2019). www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"issue":"10049","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway JD","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388(10049), 1081\u20131088 (2016).","journal-title":"Lancet"},{"issue":"2","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67(2), 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"e_1_3_4_7_2","unstructured":"WHO. Hepatitis B\u2014Key Facts (2019). www.who.int\/en\/news-room\/fact-sheets\/"},{"issue":"10","key":"e_1_3_4_8_2","first-page":"656","article-title":"Discontinuation of nucleoside analogues in hepatitis B virus infection","volume":"9","author":"Lampertico P","year":"2013","unstructured":"Lampertico P. Discontinuation of nucleoside analogues in hepatitis B virus infection. Gastroenterol. Hepatol. (NY). 9(10), 656\u2013658 (2013).","journal-title":"Gastroenterol. Hepatol. (NY)."},{"key":"e_1_3_4_9_2","unstructured":"NHS. Conditions hepatitis b; treatment (2019). www.nhs.uk\/conditions\/hepatitis-b\/treatment\/"},{"issue":"5","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0016-5085(98)70318-X","article-title":"Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial","volume":"114","author":"Sokal EM","year":"1998","unstructured":"Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 114(5), 988\u2013995 (1998).","journal-title":"Gastroenterology"},{"issue":"4","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4), 1560\u20131599 (2018).","journal-title":"Hepatology"},{"key":"e_1_3_4_12_2","unstructured":"NICE. Hepatitis B (chronic). Appendices H-0 (2013). www.nice.org.uk\/guidance\/cg165\/evidence\/cg165-hepatitis-b-chronic-appendices-ho2"},{"issue":"8","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/MEG.0000000000000376","article-title":"Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis","volume":"27","author":"Govan L","year":"2015","unstructured":"Govan L, Wu O, Xin Y, Hutchinson SJ, Hawkins N. Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis. Eur. J. Gastroenterol. Hepatol. 27(8), 882\u2013894 (2015).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","article-title":"Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials","volume":"8","author":"Wong WWL","year":"2019","unstructured":"Wong WWL, Pechivanoglou P, Wong J Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst. Rev. 8(1), 207 (2019).","journal-title":"Syst. Rev."},{"issue":"7","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6(7), e1000097 (2009).","journal-title":"PLoS Med."},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JPT","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).","journal-title":"BMJ"},{"issue":"1","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault NA","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63(1), 261\u2013283 (2016).","journal-title":"Hepatology"},{"issue":"4","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok AS","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology 66(4), 1296\u20131313 (2017).","journal-title":"Hepatology"},{"issue":"26","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau GKK","year":"2005","unstructured":"Lau GKK, Piratvisuth T, Luo KX Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682\u20132695 (2005).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","article-title":"Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B","volume":"13","author":"Dakin H","year":"2010","unstructured":"Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 13(8), 934\u2013945 (2010).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker G","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med. Res. Methodol. 15(1), 58 (2015).","journal-title":"BMC Med. Res. Methodol."},{"issue":"2","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial","volume":"47","author":"Hou J","year":"2008","unstructured":"Hou J, Yin Y-K, Xu D Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47(2), 447\u2013454 (2008).","journal-title":"Hepatology"},{"issue":"5","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","article-title":"Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B","volume":"48","author":"Sung JJY","year":"2008","unstructured":"Sung JJY, Lai J-Y, Zeuzem S Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol. 48(5), 728\u2013735 (2008).","journal-title":"J. Hepatol."},{"issue":"11","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","article-title":"Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial","volume":"147","author":"Chan HLY","year":"2007","unstructured":"Chan HLY, Heathcote EJ, Marcellin P Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med. 147(11), 745\u2013754 (2007).","journal-title":"Ann. Intern. Med."},{"issue":"31","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.3748\/wjg.v13.i31.4264","article-title":"A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B","volume":"13","author":"Ren F-Y","year":"2007","unstructured":"Ren F-Y, Piao D-M, Piao X-X. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J. Gastroenterol. 13(31), 4264\u20134267 (2007).","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/AAC.00088-07","article-title":"Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B","volume":"51","author":"Kaymakoglu S","year":"2007","unstructured":"Kaymakoglu S, Oguz D, Gur G Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob. Agents Chemother. 51(8), 3020\u20133022 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","article-title":"A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone","volume":"142","author":"Chan HL-Y","year":"2005","unstructured":"Chan HL-Y, Leung NW-Y, Hui AY A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann. Intern. Med. 142(4), 240\u2013250 (2005).","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"e_1_3_4_28_2","first-page":"889","article-title":"Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group","volume":"29","author":"Tassopoulos NC","year":"1999","unstructured":"Tassopoulos NC, Volpes R, Pastore G Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29(3), 889\u2013896 (1999).","journal-title":"Hepatology"},{"issue":"17","key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag JL","year":"1999","unstructured":"Dienstag JL, Schiff ER, Wright TL Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341(17), 1256\u20131263 (1999).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai C-L","year":"2006","unstructured":"Lai C-L, Shouval D, Lok AS Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354(10), 1011\u20131020 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"9454","key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen HLA","year":"2005","unstructured":"Janssen HLA, van Zonneveld M, Senturk H Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454), 123\u2013129 (2005).","journal-title":"Lancet"},{"issue":"10","key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang T-T","year":"2006","unstructured":"Chang T-T, Gish RG, de Man R A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354(10), 1001\u20131010 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis SJ","year":"2003","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348(9), 800\u2013807 (2003).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin P","year":"2004","unstructured":"Marcellin P, Lau GKK, Bonino F Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351(12), 1206\u20131217 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin P","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359(23), 2442\u20132455 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"e_1_3_4_36_2","first-page":"619.e1","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B","volume":"143","author":"Lok AS","year":"2012","unstructured":"Lok AS, Trinh H, Carosi G Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 143(3), 619.e1\u2013628.e1 (2012).","journal-title":"Gastroenterology"},{"issue":"3","key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12072-007-9009-2","article-title":"Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China","volume":"1","author":"Yao G","year":"2007","unstructured":"Yao G, Chen C, Lu W Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol. Int. 1(3), 365\u2013372 (2007).","journal-title":"Hepatol. Int."},{"issue":"25","key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai C-L","year":"2007","unstructured":"Lai C-L, Gane E, Liaw Y-F Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357(25), 2576\u20132588 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"e_1_3_4_39_2","first-page":"CR56","article-title":"Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study","volume":"15","author":"Papadopoulos VP","year":"2009","unstructured":"Papadopoulos VP, Chrysagis DN, Protopapas AN, Goulis IG, Dimitriadis GT, Mimidis KP. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Med. Sci. Monit. 15(2), CR56\u2013CR61 (2009).","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir","volume":"49","author":"Leung N","year":"2009","unstructured":"Leung N, Peng C-Y, Hann H-W Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 49(1), 72\u201379 (2009).","journal-title":"Hepatology"},{"issue":"14","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4103\/0366-6999.235880","article-title":"Efficacy of pegylated interferon monotherapy versus sequential therapy of entecavir and pegylated interferon in hepatitis B e antigen-positive hepatitis B patients: a randomized, multicenter, Phase IIIb open-label study (POTENT Study)","volume":"131","author":"Jun DW","year":"2018","unstructured":"Jun DW, Ahn SB, Kim TY Efficacy of pegylated interferon monotherapy versus sequential therapy of entecavir and pegylated interferon in hepatitis B e antigen-positive hepatitis B patients: a randomized, multicenter, Phase IIIb open-label study (POTENT Study). Chin. Med. J. (Engl.) 131(14), 1645\u20131651 (2018).","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"1","key":"e_1_3_4_42_2","first-page":"36","article-title":"Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of peg-IFN alpha-2a therapy: an open-labelled, randomized, controlled, \u201creal-life\u201d trial","volume":"24","author":"Luo XD","year":"2017","unstructured":"Luo XD, Chen XF, Zhou Y, Chen XP. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of peg-IFN alpha-2a therapy: an open-labelled, randomized, controlled, \u201creal-life\u201d trial. J. Viral Hepat. 24(Suppl. 1), 36\u201342 (2017).","journal-title":"J. Viral Hepat."},{"issue":"4","key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3350\/cmh.2016.0040","article-title":"Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"23","author":"Lee KS","year":"2017","unstructured":"Lee KS, Kweon Y-O, Um S-H Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clin. Mol. Hepatol. 23(4), 331\u2013339 (2017).","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12876-017-0657-y","article-title":"Addition of nucleoside analogues to peg-IFN alpha-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNalpha-2a: a randomized controlled trial","volume":"17","author":"Xu Y","year":"2017","unstructured":"Xu Y, Wang X, Liu Z Addition of nucleoside analogues to peg-IFN alpha-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNalpha-2a: a randomized controlled trial. BMC Gastroenterol. 17(1), 102 (2017).","journal-title":"BMC Gastroenterol."},{"issue":"8","key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S2468-1253(17)30083-3","article-title":"Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial","volume":"2","author":"de Niet A","year":"2017","unstructured":"de Niet A, Jansen L, Stelma F Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. Lancet Gastroenterol. Hepatol. 2(8), 576\u2013584 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind,Phase III, non-inferiority trial","volume":"1","author":"Buti M","year":"2016","unstructured":"Buti M, Gane E, Seto WK Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind,Phase III, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1(3), 196\u2013206 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, Phase III, non-inferiority trial","volume":"1","author":"Chan HLY","year":"2016","unstructured":"Chan HLY, Fung S, Seto WK Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, Phase III, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1(3), 185\u2013195 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12902","article-title":"Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients","volume":"48","author":"Koike K","year":"2018","unstructured":"Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. Hepatol. Res. 48(1), 59\u201368 (2018).","journal-title":"Hepatol. Res."},{"issue":"32","key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4254\/wjh.v8.i32.1402","article-title":"Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study","volume":"8","author":"Krastev Z","year":"2016","unstructured":"Krastev Z, Petrova D, Kotzev I Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. World J. Hepatol. 8(32), 1402\u20131413 (2016).","journal-title":"World J. Hepatol."},{"issue":"31","key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"e4471","DOI":"10.1097\/MD.0000000000004471","article-title":"CONSORT: effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: a prospective, randomized study","volume":"95","author":"Zhang K","year":"2016","unstructured":"Zhang K, Cao H, Liang J CONSORT: effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: a prospective, randomized study. Medicine (Balt.) 95(31), e4471 (2016).","journal-title":"Medicine (Balt.)"},{"issue":"3","key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1111\/hepr.12743","article-title":"Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial","volume":"47","author":"Sriprayoon T","year":"2017","unstructured":"Sriprayoon T, Mahidol C, Ungtrakul T Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Hepatol. Res. 47(3), E161\u2013E168 (2017).","journal-title":"Hepatol. Res."},{"issue":"1","key":"e_1_3_4_52_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin P","year":"2016","unstructured":"Marcellin P, Ahn SH, Ma X Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150(1), 134\u2013144.e10 (2016).","journal-title":"Gastroenterology"},{"issue":"4","key":"e_1_3_4_53_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/jgh.12835","article-title":"Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients","volume":"30","author":"Liang X","year":"2015","unstructured":"Liang X, Cheng J, Sun Y Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. J. Gastroenterol. Hepatol. 30(4), 748\u2013755 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"e_1_3_4_54_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jvh.12313","article-title":"Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial","volume":"22","author":"Hou JL","year":"2015","unstructured":"Hou JL, Gao ZL, Xie Q Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J. Viral Hepat. 22(2), 85\u201393 (2015).","journal-title":"J. Viral Hepat."},{"issue":"8","key":"e_1_3_4_55_2","first-page":"e10813","article-title":"Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy","volume":"14","author":"Wen Z","year":"2014","unstructured":"Wen Z, Zhang H, Zhang M Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy. Hepat. Mon. 14(8), e10813 (2014).","journal-title":"Hepat. Mon."},{"issue":"12","key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B \u201ce\u201d antigen-positive chronic hepatitis B","volume":"59","author":"Xie Q","year":"2014","unstructured":"Xie Q, Zhou H, Bai X A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B \u201ce\u201d antigen-positive chronic hepatitis B. Clin. Infect. Dis. 59(12), 1714\u20131723 (2014).","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"e_1_3_4_57_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11596-014-1312-2","article-title":"Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study","volume":"34","author":"Liu Y-H","year":"2014","unstructured":"Liu Y-H, Wu T, Sun N Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. J. Huazhong Univ. Sci. Tech. Med. Sci. 34(4), 542\u2013547 (2014).","journal-title":"J. Huazhong Univ. Sci. Tech. Med. Sci."},{"issue":"28","key":"e_1_3_4_58_2","doi-asserted-by":"crossref","first-page":"9486","DOI":"10.3748\/wjg.v20.i28.9486","article-title":"Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B","volume":"20","author":"Li C-Z","year":"2014","unstructured":"Li C-Z, Hu J-J, Xue J-Y Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J. Gastroenterol. 20(28), 9486\u20139496 (2014).","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3851\/IMP2754","article-title":"Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study","volume":"19","author":"Tseng K-C","year":"2014","unstructured":"Tseng K-C, Chen C-Y, Tsai H-W Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study. Antivir. Ther. 19(8), 755\u2013764 (2014).","journal-title":"Antivir. Ther."},{"issue":"4","key":"e_1_3_4_60_2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/hep.26885","article-title":"The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study","volume":"59","author":"Sun J","year":"2014","unstructured":"Sun J, Xie Q, Tan D The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 59(4), 1283\u20131292 (2014).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12072-013-9488-2","article-title":"Two-year results of a randomized, Phase III comparative trial of telbivudine versus lamivudine in Chinese patients","volume":"8","author":"Jia J-D","year":"2014","unstructured":"Jia J-D, Hou J-L, Yin Y-K Two-year results of a randomized, Phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatol. Int. 8(1), 72\u201382 (2014).","journal-title":"Hepatol. Int."},{"issue":"8","key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/1751-2980.12065","article-title":"Extended treatment with peginterferon alpha-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion","volume":"14","author":"Cao ZH","year":"2013","unstructured":"Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. Extended treatment with peginterferon alpha-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. J. Dig. Dis. 14(8), 446\u2013450 (2013).","journal-title":"J. Dig. Dis."},{"issue":"5","key":"e_1_3_4_63_2","first-page":"636","article-title":"Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients","volume":"17","author":"Wang H","year":"2013","unstructured":"Wang H, Ji YY, Yao GB Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients. Eur. Rev. Med. Pharmacol. Sci. 17(5), 636\u2013643 (2013).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"6","key":"e_1_3_4_64_2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clinre.2012.05.012","article-title":"Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B","volume":"36","author":"He Z","year":"2012","unstructured":"He Z, Wang J, Liu K Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clin. Res. Hepatol. Gastroenterol. 36(6), 592\u2013597 (2012).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"8","key":"e_1_3_4_65_2","first-page":"12329","article-title":"Clinical efficacy of tenofovir and entecavir in the treatment of chronic hepatitis B infection in patients na\u00efve to nucleosides and their analogues therapy","volume":"10","author":"Zhang Shuang Li","year":"2017","unstructured":"Zhang Shuang Li, Wei Lu, Ping Ma. Clinical efficacy of tenofovir and entecavir in the treatment of chronic hepatitis B infection in patients na\u00efve to nucleosides and their analogues therapy. Int. J. Clin. Exp. Med. 10(8), 12329\u201312335 (2017).","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"9","key":"e_1_3_4_66_2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin P","year":"2003","unstructured":"Marcellin P, Chang T-T, Lim SG Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348(9), 808\u2013816 (2003).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"e_1_3_4_67_2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"129","author":"Lai C-L","year":"2005","unstructured":"Lai C-L, Leung N, Teo E-K A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2), 528\u2013536 (2005).","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_3_4_68_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12072-013-9488-2","article-title":"Two-year results of a randomized, Phase III comparative trial of telbivudine versus lamivudine in Chinese patients","volume":"8","author":"Jia J-D","year":"2014","unstructured":"Jia J-D, Hou J-L, Yin Y-K Two-year results of a randomized, Phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatol. Int. 8(1), 72\u201382 (2014).","journal-title":"Hepatol. Int."},{"issue":"1","key":"e_1_3_4_69_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian\u2013Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin SK","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK Asian\u2013Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10(1), 1\u201398 (2016).","journal-title":"Hepatol. Int."},{"issue":"2","key":"e_1_3_4_70_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster Erik HCJ","year":"2008","unstructured":"Buster Erik HCJ, Flink HJ, Cakaloglu Y Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135(2), 459\u2013467 (2008).","journal-title":"Gastroenterology"},{"key":"e_1_3_4_71_2","unstructured":"World Health Organization. Hepatitis - fact sheet. [Hepatitis B control]. www.wpro.who.int\/china\/mediacentre\/factsheets\/hepatitis\/en\/"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:12:30Z","timestamp":1679231550000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":69,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.2217\/cer-2020-0068"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0068","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}